Sweden Pharmacovigilance Market Outlook

Synopsis
The above chart is Sweden Pharmacovigilance Market Outlook (2018 to 2032)

Market Dynamics

the swedish pharmacovigilance market is predicted to expand steadily over the next few years due to the presence of leading pharmaceutical companies, the oecd pharmaceutical safety program, and a favorable regulatory environment. the sweden's pharmacovigilance market boasts of a strong research base in drug development, safety and efficacy and also provides an array of healthcare services. furthermore, the number of drug products, their complexity, and the increasing number of innovative medicines have led to increased demand for pharmacovigilance activities in sweden. considerable increase in the number of patients on medications, combined with improved access to advanced technologies such as three-dimensional imaging and gene sequencing is likely to propel the pharmacovigilance market in the swedish health care system. the key players in sweden’s pharmacovigilance market are international pharmaceutical companies such as astrazeneca, glaxosmithkline, novo nordisk, pfizer, and merck. additionally, there is significant participation from multinational company-affiliated health care units, swedish organizations such as svenskt kvalitets register, pharmaceutical safety authority, and swedish national board of health and welfare. sweden’s pharmaceutical safety program is one of the world’s most advanced systems for monitoring and reporting suspected adverse drug reactions. it implements innovative practices in the fields of data collection, reporting, analyzing, and determining safety signals related to adverse drug effects. the program works in close cooperation with the international medical communities, including the european medicines agency (ema). sweden is also a key player in the development of the european medicines agency’s pharmacovigilance risk assessment committee (prac). the growing number of biologic drugs that are produced in sweden and have higher levels of increased safety requirements as compared to non-biologics is further anticipated to drive the swedish pharmacovigilance market. moreover, the increasing adoption of risk management and benefit-risk assessment frameworks across the world is likely to contribute to the growth of the pharmacovigilance market within sweden. in conclusion, it can be summarised that the sweden pharmacovigilance market is expected to show a steady growth over the forecast period. a number of positive developments related to the drug safety system and its regulations in sweden are likely to catalyse the growth of the demand for pharmacovigilance activities.